Therapure to manufacture VBI coronavirus vaccines

By The Science Advisory Board staff writers

August 18, 2020 -- Therapure Biomanufacturing has signed an agreement with VBI Vaccines for the manufacture of its coronavirus vaccine candidates.

Under the agreement, Therapure will be responsible for the manufacturing of the vaccine drug substance as well as the aseptic fill of the drug product at its facility in Mississauga, Ontario. The company will provide current good manufacturing practice biomanufacturing capabilities to advance the vaccine candidates through clinical studies.

VBI is using its enveloped virus-like particle (eVLP) platform for the development of a preventative pancoronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS), in collaboration with the National Research Council of Canada.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Copyright © 2020

Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter